Xilio Therapeutics, Inc. (XLO)
XLO moved a median of -0.28% 30 minutes after news, and -0.33% by the close. How XLO actually reacts to news — the realized, point-in-time move the market made, measured across 255 labeled events over the last three years with zero look-ahead.
XLO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 237 |
| 30-min | -0.28% | 36% | 254 |
| 60-min | 0.00% | 49% | 254 |
| to close | -0.33% | 43% | 252 |
| Middle 50% of XLO reactions | -2.07% to +1.31% |
|---|---|
| Median reaction (30-min) | -0.28% |
| Measured reactions | 255 |
Half of all Xilio Therapeutics, Inc. news events land between -2.07% and +1.31% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XLO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XLO's baseline. Nothing else.
Recent XLO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +0.44% | |
| Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer | Press release | GlobeNewswire | +0.11% | -1.74% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.13% | +2.04% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.42% | |
| Form 8-K Xilio Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.42% | |
| Form S-8 Xilio Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.42% | |
| Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates | Press release | GlobeNewswire | +0.00% | -1.42% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -0.85% | |
| Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | Press release | GlobeNewswire | +0.11% | +4.27% | |
| Form 8-K Xilio Therapeutics, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +0.97% | |
| Form EFFECT Xilio Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -2.60% | |
| Form S-3/A Xilio Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +1.67% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.39% | +0.00% | |
| Form 8-K Xilio Therapeutics, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +0.00% | |
| Form S-3 Xilio Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.39% | +0.00% | |
| Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | Press release | GlobeNewswire | -0.39% | +0.00% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.90% | -0.51% | |
| Form ARS Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.82% | -0.89% | |
| Form DEF 14A Xilio Therapeutics, Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +3.82% | -0.89% | |
| Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 | Press release | GlobeNewswire | -0.23% | -1.97% | |
| Form 8-K Xilio Therapeutics, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +7.13% | +1.95% | |
| Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | Press release | GlobeNewswire | — | -2.68% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.59% | -0.47% | |
| Form 10-K Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.00% | -1.63% | |
| Form 8-K Xilio Therapeutics, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | -1.63% | |
| Form S-8 Xilio Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.00% | -1.63% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -3.00% | -1.63% | |
| Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting | Press release | GlobeNewswire | +0.00% | +2.98% | |
| Form 8-K Xilio Therapeutics, Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -2.96% | +0.26% | |
| Xilio Therapeutics Announces 1-for-14 Reverse Stock Split | Press release | GlobeNewswire | -2.96% | +0.26% | |
| Form 8-K Xilio Therapeutics, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +2.97% | +0.19% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.25% | +3.40% | |
| Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | +0.25% | +3.40% | |
| Form 8-K Xilio Therapeutics, Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +2.11% | |
| Form 8-K Xilio Therapeutics, Inc. For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +0.07% | |
| Xilio Therapeutics Announces Pricing of Underwritten Offering | Press release | GlobeNewswire | -4.02% | +6.46% | |
| Form DEF 14A Xilio Therapeutics, Inc. For: Feb 23 | SEC filing · Form DEF | SEC EDGAR | -0.63% | -0.61% | |
| Form PRE 14A Xilio Therapeutics, Inc. For: Jan 16 | SEC filing · Form PRE | SEC EDGAR | -1.22% | -1.06% | |
| Form 8-K Xilio Therapeutics, Inc. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +1.33% | |
| Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates | Press release | GlobeNewswire | -0.55% | +1.33% | |
| Form 8-K Xilio Therapeutics, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.03% | |
| Form 8-K Xilio Therapeutics, Inc. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -1.08% | |
| Form S-8 Xilio Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.46% | -1.08% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.67% | — | |
| Form 8-K Xilio Therapeutics, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | — | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.67% | — | |
| Form 8-K Xilio Therapeutics, Inc. For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -3.49% | -5.06% | |
| Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | Press release | GlobeNewswire | -3.49% | -5.06% | |
| Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | Press release | GlobeNewswire | -3.49% | -5.06% | |
| Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.44% | -5.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XLO section they belong to.
Where else XLO is measured.
XLO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Xilio Therapeutics, Inc.'s median reaction calculated?
Every labeled XLO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 255 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of XLO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XLO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.